Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Psychiatry Res ; 337: 115949, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38795698

RESUMO

Ketamine, a N-methyl-D-aspartate (NMDA) antagonist, is used for treatment-resistant depression (TRD). Recent studies have shown that there are increased levels of pro-inflammatory cytokines in individuals with major depressive disorder (MDD) and those with higher levels of oxidative stress markers have a decreased or null response to conventional antidepressants. Glutathione (GSH) as an antioxidant adjuvant to ketamine has not been well studied. This double-blind study with 30 patients divided into 2 groups of 15 each, aimed to determine if GSH, added to standard ketamine infusion (GSH+K), rendered better outcomes in MDD patients versus patients receiving ketamine infusions with a normal saline placebo (K+NS). There were significant drops in BDI-II scores from day 1 to day 14, PHQ- scores from day 1 to day 14 and PHQ-9 scores day 14 to day 28, suggesting the overall treatment was effective. There were no statistically significant differences between the groups over time. However, a sustained improvement in depressive symptoms was observed for 14 days post-infusion in both groups.


Assuntos
Transtorno Depressivo Maior , Glutationa , Ketamina , Humanos , Ketamina/administração & dosagem , Ketamina/farmacologia , Ketamina/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Feminino , Masculino , Adulto , Método Duplo-Cego , Pessoa de Meia-Idade , Quimioterapia Combinada , Antidepressivos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico , Resultado do Tratamento , Infusões Intravenosas , Escalas de Graduação Psiquiátrica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...